Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 7, 2010, Pages 926-927

  Douglass, J A ^a   Carroll, K ^a   Voskamp, A ^a   Bourke, P ^a   Wei, A ^a   O'Hehir, R E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Omalizumab; Tryptase

Indexed keywords

CD2 ANTIGEN; CLADRIBINE; IMMUNOGLOBULIN E; INTERLEUKIN 2 RECEPTOR ALPHA; OMALIZUMAB; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANAPHYLAXIS; ARTICLE; BONE MARROW BIOPSY; BRAIN HYPOXIA; CASE REPORT; DIARRHEA; FEMALE; FLUSHING; HEART ARREST; HEART PALPITATION; HUMAN; HYPOTENSION; MAST CELL LEUKEMIA; MEDIATOR RELEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE; URTICARIA; COMPLICATION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PATHOPHYSIOLOGY;

ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEART ARREST; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED;

EID: 77953105527     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.02259.x     Document Type: Article

References (6)

1. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007 37 : 435 453.
2. Carter M, Robyn J, Bressler P, Walker J, Shapiro G, Metcalfe D. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007 119 : 1550 1551.
3. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008 63 : 376 378.
4. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc Epsilon RI expression and function. J Allergy Clin Immunol 2004 114 : 527 530.
5. Drew AC, Eusebius NP, Kenins L, de Silva HR, Suphioglu C, Rolland JM et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human lymphocyte reactivity. J Immunol 2004 173 : 5872 5879.
6. Nopp A, Johannson SG, Ankerst J, Bylin G, Cordell LO, Grönneberg R et al. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006 61 : 298 302.